PT-141 (Bremelanotide) dosage chart
This summary table compares available dose amounts and schedules by administration route.
| Route | Dose | Frequency & duration |
|---|---|---|
| Injectable | 1.75 mg | As needed · At least 45 minutes before anticipated sexual activity; maximum one dose in 24 hours and 8 doses per month · Reassess after 8 weeks if no improvement |
| Intranasal | 20 mg | Event based · Review at 8 wk |
PT-141 (Bremelanotide) dosage by administration route
PT-141 (Bremelanotide) injectable dosage
Vyleesi is given as a 1.75 mg subcutaneous dose at least 45 minutes before anticipated sexual activity. Do not use more than one dose in 24 hours or eight doses per month. Discontinue after 8 weeks if there is no improvement. An alternative schedule uses lower reported per-event amounts of 0.75 mg and 1.25 mg alongside 1.75 mg. The approved Vyleesi dose remains 1.75 mg with its labeled frequency limits; the lower reported amounts are not alternative approved starting doses.[1][9]
Bremelanotide acts on melanocortin receptors involved in sexual desire. Vyleesi is indicated for acquired, generalized hypoactive sexual desire disorder in premenopausal women.[2][3][1]
PT-141 (Bremelanotide) intranasal dosage
Reported-use amounts for PT-141 (Bremelanotide) are 20 mg per administration, per event, with a review at 8 wk.[8]
Bremelanotide acts on melanocortin receptors involved in sexual desire. Vyleesi is indicated for acquired, generalized hypoactive sexual desire disorder in premenopausal women.[6][7][2][3][1][8]
PT-141 (Bremelanotide) dosage calculator
Convert your chosen PT-141 (Bremelanotide) amount into volume and U-100 syringe units. Adjust the inputs to match your vial and preparation.
PT-141 (Bremelanotide) safety and side effects
Approval and product quality
Vyleesi bremelanotide injection is FDA-approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women; compounded PT-141 and other populations are separate.[1][5]
Side effects and long-term safety
Nausea, flushing, blood-pressure effects and local injection symptoms are relevant adverse effects. Compounded PT-141, populations outside the Vyleesi indication and use beyond label limits have a different safety profile from the labeled product.[1][2]
Route-specific dosing limits
Cardiovascular status, pregnancy, pigmentation changes and interactions affecting oral-medication absorption require separate attention. Reported-use intranasal schedules and additional protocol patterns are not established human treatment regimens or approved product instructions.[1][2][9][8]
